|
Apr 19, 2021
|
Two HEPLISAV-B Abstracts Selected for Oral Presentation at the 2021 Annual Conference on Vaccinology Research (ACVR)
|
|
|
Apr 06, 2021
|
Positive Phase 1/2 Results for Valneva's Inactivated COVID-19 Vaccine Candidate Using Dynavax's CpG 1018™ Adjuvant
|
|
|
Apr 02, 2021
|
Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
|
Mar 24, 2021
|
Clover Biopharmaceuticals and Dynavax Announce First Participants Dosed in SPECTRA, a Global Phase 2/3 Clinical Trial for Adjuvanted S-Trimer COVID-19 Vaccine Candidate
|
|
|
Mar 01, 2021
|
Dynavax to Present at the H.C. Wainwright Virtual 2021 Global Life Sciences Conference
|
|
|
Mar 01, 2021
|
Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
|
Feb 25, 2021
|
Dynavax Announces Fourth Quarter and Full Year 2020 Financial Results
|
|
|
Feb 19, 2021
|
Dynavax Announces European Commission Marketing Authorization for HEPLISAV B®, a 2 Dose Adult Hepatitis B Adjuvanted Vaccine
|
|
|
Feb 16, 2021
|
Dynavax to Present at the Cowen 41st Annual Health Care Conference
|
|
|
Feb 11, 2021
|
Dynavax to Report Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on February 25, 2021
|
|
